Literature DB >> 31263925

[Antioxidants and selenium should not be lumped together into one category-evaluation of supplementation during chemotherapy or radiotherapy for breast cancer].

Marc D Piroth1, Ralph Mücke2, Oliver Micke3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31263925     DOI： 10.1007/s00066-019-01486-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort.

Authors:  Heather Greenlee; Marilyn L Kwan; Lawrence H Kushi; Jun Song; Adrienne Castillo; Erin Weltzien; Charles P Quesenberry; Bette J Caan
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

2.  Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study.

Authors:  Sarah Nechuta; Wei Lu; Zhi Chen; Ying Zheng; Kai Gu; Hui Cai; Wei Zheng; Xiao Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-21       Impact factor: 4.254

3.  Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology.

Authors:  Ralph Muecke; Lutz Schomburg; Michael Glatzel; Regina Berndt-Skorka; Dieter Baaske; Berthold Reichl; Jens Buentzel; Guenter Kundt; Franz J Prott; Alexander Devries; Guenther Stoll; Klaus Kisters; Frank Bruns; Ulrich Schaefer; Norman Willich; Oliver Micke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-03       Impact factor: 7.038

4.  Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization.

Authors:  Ralph Muecke; Oliver Micke; Lutz Schomburg; Michael Glatzel; Berthold Reichl; Klaus Kisters; Ulrich Schaefer; Jutta Huebner; Hans T Eich; K Fakhrian; Irenaeus A Adamietz; Jens Buentzel
Journal:  Integr Cancer Ther       Date:  2014-07-11       Impact factor: 3.279

5.  Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.

Authors:  Dieter Flesch-Janys; Tracy Slanger; Elke Mutschelknauss; Silke Kropp; Nadia Obi; Eik Vettorazzi; Wilhelm Braendle; Gunter Bastert; Stefan Hentschel; Jürgen Berger; Jenny Chang-Claude
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

6.  Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy.

Authors:  Audrey Y Jung; Xinting Cai; Kathrin Thoene; Nadia Obi; Stefanie Jaskulski; Sabine Behrens; Dieter Flesch-Janys; Jenny Chang-Claude
Journal:  Am J Clin Nutr       Date:  2019-01-01       Impact factor: 7.045

7.  Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial.

Authors:  Ralph Muecke; Oliver Micke; Lutz Schomburg; Jens Buentzel; Michael Glatzel; Dieter Baaske; Regina Berndt-Skorka; Franz J Prott; Berthold Reichl; Klaus Kisters; Ulrich Schaefer; Jutta Huebner; Hans Th Eich; Guenther Kundt; Irenaeus A Adamietz
Journal:  Radiat Oncol       Date:  2013-03-25       Impact factor: 3.481

Review 8.  Updates on clinical studies of selenium supplementation in radiotherapy.

Authors:  Irma M Puspitasari; Rizky Abdulah; Chiho Yamazaki; Satomi Kameo; Takashi Nakano; Hiroshi Koyama
Journal:  Radiat Oncol       Date:  2014-05-29       Impact factor: 3.481
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.